Nanox Announces Distribution Agreement with Medworks for Nanox.AI in Greece
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nanox Imaging (NASDAQ: NNOX) entered into a non-exclusive distribution agreement with Medworks to expand the commercial reach of Nanox.AI in Greece.
Medworks will initially resell HealthOST, Nanox.AI’s FDA-cleared and CE-marked AI-based bone solution. The agreement builds on an existing deployment in Athens. Nanox intends to use Medworks’ Greek market presence and sales, technical support, applications and customer service capabilities to support expansion. The companies may explore broader collaboration in the future.
Positive
- Minor pointMedworks distribution agreement adds a non-exclusive HealthOST reseller in Greece to support Nanox.AI’s commercial expansion.
Negative
- None.
Details
Market move: NNOX +3.67% vs previous close. Greece distribution agreement
On Nov 13, the day this news came out, the latest delayed price for NNOX is 3.67% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $0.33. Relative volume is exceptionally heavy at 5.2x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Previous AI Reports
-
HealthOST distribution agreement with Technologic to commercialize the bone solution in Italy.
-
Exclusive three-year HealthOST reseller agreement, contingent on minimum annual license commitments.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fda-cleared regulatory
ce-marked regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Building on Nanox.AI's existing deployment in Athens, the agreement supports commercial expansion in Greece through Medworks' established market presence.
PETACH TIKVA, Israel, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that it has entered into a non-exclusive distribution agreement with Medworks LTD (“Medworks”) to support the commercial expansion of Nanox.AI’s HealthOST solution in Greece.
Under the agreement, Medworks has been appointed as a non-exclusive reseller of HealthOST, Nanox.AI’s FDA-cleared and CE-marked AI-based bone solution, in Greece, leveraging its established presence and experience serving healthcare providers across the country. The agreement initially focuses on HealthOST and establishes a commercial relationship through which the companies may explore broader collaboration in the future. Medworks has experience in diagnostic imaging and other medical technologies and provides sales, technical support, applications and customer service capabilities in the Greek market. Medworks’ published company profile describes experience with medical imaging technologies including ultrasound, CT, MRI, X-ray and mammography equipment, as well as cardiology equipment.
The agreement builds on Nanox.AI’s existing presence in Greece and is intended to support the Company’s continued commercial expansion in the Greek market.
“Our agreement with Medworks represents an important step in expanding the commercial reach of Nanox.AI,” said Erez Meltzer, Chief Executive Officer of Nanox. “Medworks’ established presence and experience in the Greek healthcare market will support our efforts to expand access to Nanox.AI and strengthen our presence in Greece.”
“We are pleased to partner with Nanox and introduce Nanox.AI to healthcare providers across Greece,” said Tassos Zachos, Managing Director at Medworks LTD. “By combining Nanox’s AI-powered technology with our experience and relationships in the Greek healthcare market, we look forward to supporting its adoption across the country.”
About Medworks
Medworks LTD is a Greece-based medical technology company supplying and supporting medical imaging, cardiology and other medical equipment. Founded in 2009, the company has experience in the trade and support of high-technology medical systems and operates dedicated customer service, technical support, applications and sales departments. MEDWORKS Company Profile.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC X, a multi-source digital tomosynthesis system designed to make advanced 3D imaging accessible in more clinical settings; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
The Nanox.ARC X was selected as one of TIME’s Best Inventions of 2026.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.
About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit www.nanox.vision/ai.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.